• Scientifc Lead Sandor Kantor has a speaker slot at the CNS Therapeutics Xchange on 26th May see conference page for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
  • the effectiveness of a clinically relevant dose of ketamine...
  • Head to 2021 conferences page to see titles of abstracts...
 

Cognitive Disorders

Transpharmation has considerable understanding in preclinical cognition research gained through decades of experience running disease area portfolios for Alzheimer’s disease, Parkinson’s disease and Schizophrenia within GlaxoSmithKline. Importantly, our highly skilled technical staff appreciate the subtleties involved in evaluating rodent cognitive processes, ensuring all our assays are highly robust and reproducible.

We focus on delivering carefully selected cognition models which are disease-relevant thereby offering the option to evaluate NCEs against pharmacologically induced cognition impairments, (e.g scopolamine) or natural impairments, (age, test parametric manipulation) across multiple disease areas.

Examples of the models we offer include the following:

  • Novel object recognition
    • temporal deficit
    • pharmacological deficit, (scopolamine, sub-chronic PCP)
  • Delayed-non-match to position
  • Reversal learning
  • Attentional set shifting

cognitiveThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design